Tegavivint and Osimertinib Combo Improved NSCLC Outcomes
In a phase 1b study, patients with EGFR-mutated lung cancer saw tumor reduction and longer survival using this drug pair.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Should medical research prioritize funding for combination therapies to overcome cancer drug resistance?
A 2026 phase 1b study found that combining the drug tegavivint with osimertinib showed clinical promise for patients with non-small cell lung cancer (NSCLC). This combination therapy resulted in a 79% objective response rate among the 19 evaluable participants.
Why it matters
The study addresses a common challenge in treating EGFR-mutated NSCLC, where drug-tolerant cancer cells often survive standard therapy. By targeting the beta-catenin pathway, this combination seeks to disrupt the mechanisms these persistent cells use to remain active.
In a phase 1b trial of 19 evaluable patients with NSCLC, the combination of tegavivint and osimertinib yielded a median progression-free survival of 19.9 months and a median overall survival of 48.8 months. Researchers also observed a 65% mean decrease in tumor burden.
The players
ASCO
The American Society of Clinical Oncology is a professional organization representing physicians and oncology professionals focused on cancer research and patient care.
The details
Tegavivint functions by binding to transducin beta-like protein 1, which inhibits Wnt/beta-catenin signaling in cancer cells. Osimertinib is administered to target EGFR mutations, while tegavivint addresses the increased beta-catenin transcriptional activity that allows some cancer cells to persist. Patients received 80 mg of osimertinib daily alongside weekly intravenous tegavivint doses ranging from 3 to 8 mg/kg for 4 months.
Timeline
Data from the study were presented at the 2026 ASCO Annual Meeting.
Health Landscape
The clinical findings reflect the ongoing evolution of strategies targeting drug-tolerant persister cells in lung cancer. This approach marks a significant shift in addressing how EGFR-mutated NSCLC cells survive initial systemic therapies.
This research is in the early phase 1b stage and is not currently a standard clinical treatment option. Patients with EGFR-mutated NSCLC should consult with their oncology team about ongoing clinical trials and whether they may qualify for studies investigating new combination therapies.
The takeaway
The study suggests that targeting specific signaling pathways may help improve survival rates in difficult-to-treat lung cancers. Patients interested in emerging treatment options should discuss clinical trial opportunities and potential side effects, such as rash and fatigue, with their physician.
Further reading
For more information on how researchers are working to overcome treatment resistance in patients with Cancer, visit our dedicated resource section.
Live Poll
Should medical research prioritize funding for combination therapies to overcome cancer drug resistance?
